"Venetoclax" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonEuropean Commission okays all-oral VENCLYXTO combos with time off treatment - Stock Titan
European Commission okays all-oral VENCLYXTO combos with time off treatment Stock Titan
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML - OncLive
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML OncLive
Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leuke...
Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia Nature
HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML - Targeted Oncology
HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML Targeted Oncology
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for pa...
Venetoclax Combination Therapy Shows Promising Activity in Relapsed AML - Inside Precision Medicine
Venetoclax Combination Therapy Shows Promising Activity in Relapsed AML Inside Precision Medicine
Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL - oncologynurseadvisor.com
Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL oncologynurseadvisor.com
Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients - AJMC
Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients AJMC
FDA Approves Venetoclax (Venclexta) Plus Acalabrutinib (Calquence) for Previously Untreated CLL -...
FDA Approves Venetoclax (Venclexta) Plus Acalabrutinib (Calquence) for Previously Untreated CLL Oncology News Central
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia - The New England Jou...
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia The New England Journal of Medicine
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia Nature
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Unfit AML - Targeted Oncology
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Unfit AML Targeted Oncology
FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL - OncLive
FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL OncLive
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent ther...
Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL - Targeted Oncology
Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL Targeted Oncology
Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL - OncLive
Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL OncLive
Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is char...
Fixed-Duration Pirtobrutinib Plus Venetoclax/Rituximab Yields PFS Advantage in R/R CLL/SLL - OncLive
Fixed-Duration Pirtobrutinib Plus Venetoclax/Rituximab Yields PFS Advantage in R/R CLL/SLL OncLive
Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetocl...
Choosing a BTK Inhibitor vs Time-Limited Treatment for CLL: Kerry Rogers, MD - AJMC
Choosing a BTK Inhibitor vs Time-Limited Treatment for CLL: Kerry Rogers, MD AJMC
Can Alternating Venetoclax Regimens Improve AML Outcomes? - Medscape
Can Alternating Venetoclax Regimens Improve AML Outcomes? Medscape
FDA Approval of Acalabrutinib Plus Venetoclax Brings an All-Oral, Fixed-Duration Option to Frontl...
Zanubrutinib versus Venetoclax-Obinutuzumab Fixed-Duration Therapy - OncLive
Zanubrutinib versus Venetoclax-Obinutuzumab Fixed-Duration Therapy OncLive
Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute my...
Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL - Onc...
Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL OncLive
HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute ...
The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cel...
FDA OKs Acalabrutinib/Venetoclax in CLL/SLL - Oncology Nursing News
FDA OKs Acalabrutinib/Venetoclax in CLL/SLL Oncology Nursing News
Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS - OncLive
Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS OncLive
Fixed-Duration Venetoclax Plus Obinutuzumab Yields High CR Rates, Manageable Safety in CLL/SLL - ...
Fixed-Duration Venetoclax Plus Obinutuzumab Yields High CR Rates, Manageable Safety in CLL/SLL OncLive
Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients wit...
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML - AJMC
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML AJMC
Venetoclax/Azacitidine Yields No OS Improvement in Intermediate/High Risk MDS - CancerNetwork
Venetoclax/Azacitidine Yields No OS Improvement in Intermediate/High Risk MDS CancerNetwork
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL - OncLive
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL OncLive
Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in re...
BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemi...
BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemia Nature
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a mul...
Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL -...
Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL OncLive
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Unt...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL The ASCO Post
Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy - CancerNetwork
Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy CancerNetwork
Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in T...
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified...
Analysis of interactions between posaconazole/voriconazole and venetoclax - ASM Journals
Analysis of interactions between posaconazole/voriconazole and venetoclax ASM Journals
Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemother...
Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemotherapy Penn Medicine
Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL - Targeted Oncology
Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL Targeted Oncology
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia...
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy - Vänttinen - 2026 - HemaSphere Wiley Online Library
Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsin...
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase...
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with C...
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? Lymphoma Hub
Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refr...
Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine–Venetoclax Combination i...
Data for Venetoclax/Azacitidine in Induction-Eligible AML: The PARADIGM Trial - OncLive
Data for Venetoclax/Azacitidine in Induction-Eligible AML: The PARADIGM Trial OncLive
Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL - Lymphoma Hub
Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL Lymphoma Hub
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation fo...
Tagraxofusp, Azacitidine, and Venetoclax (TAG-AZA-VEN) Triplet Therapy Shows Efficacy, Tolerabili...
Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid...
Rapid response to obinutuzumab and venetoclax in patients with nephrotic syndrome related to CLL:...
Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL - OncLive
Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL OncLive
FDA Approves Venetoclax Plus Acalabrutinib for Previously Untreated Adults With CLL - Pharmacy Times
FDA Approves Venetoclax Plus Acalabrutinib for Previously Untreated Adults With CLL Pharmacy Times
GAIA/CLL13 phase III 5‑year follow-up: Venetoclax combinations in CLL - Lymphoma Hub
GAIA/CLL13 phase III 5‑year follow-up: Venetoclax combinations in CLL Lymphoma Hub
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resista...
Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy...
Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy in Acute Myeloid Leukemia Cancer Therapy Advisor
Venetoclax Combo Shows Promise in Younger Patients With AML - Medscape
Venetoclax Combo Shows Promise in Younger Patients With AML Medscape
Factors affecting response and resistance to venetoclax in acute myeloid leukemia - Frontiers
Factors affecting response and resistance to venetoclax in acute myeloid leukemia Frontiers
The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL - OncLive
The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL OncLive
Zanubrutinib + Venetoclax for Treatment-Naive CLL/SLL (SEQUOIA Arm D) - CancerNetwork
Zanubrutinib + Venetoclax for Treatment-Naive CLL/SLL (SEQUOIA Arm D) CancerNetwork
Venetoclax/Ibrutinib Safe, Induces Durable Response in Marginal Zone Lymphoma - Targeted Oncology
Venetoclax/Ibrutinib Safe, Induces Durable Response in Marginal Zone Lymphoma Targeted Oncology
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Compar...
Zanubrutinib versus Fixed-Duration Venetoclax-Ibrutinib Combinations - OncLive
Zanubrutinib versus Fixed-Duration Venetoclax-Ibrutinib Combinations OncLive
Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC - On...
Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC OncLive
Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia - Targeted Oncology
Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia Targeted Oncology
Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL - Targeted Onco...
Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL Targeted Oncology
Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Na...
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-r...
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia Wiley Online Library
Remote-controlled CAR-T cells use venetoclax to disengage from tumors - Medical Xpress
Remote-controlled CAR-T cells use venetoclax to disengage from tumors Medical Xpress
Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML -...
Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML OncLive
Venetoclax-Based Therapy in AML: Benefits, Toxicity, and Real-World Adjustments - OncLive
Venetoclax-Based Therapy in AML: Benefits, Toxicity, and Real-World Adjustments OncLive
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute pr...
Real-World Outcomes Comparing Venetoclax and BTK Inhibitors Among Patients with Chronic Lymphocyt...
Real-World Outcomes Comparing Venetoclax and BTK Inhibitors Among Patients with Chronic Lymphocytic Leukemia Consultant360
Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL - OncLive
Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL OncLive
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newl...
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia HMP Global Learning Network
mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress ...
Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chem...
Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy The ASCO Post
Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidin...
Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive
Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL OncLive
MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial - Lymphoma Hub
MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial Lymphoma Hub
Venetoclax and the Impact on Management of Older Patients With AML - AJMC
Venetoclax and the Impact on Management of Older Patients With AML AJMC
Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL -...
Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL Oncology News Central
Venetoclax Consolidation After BTKi Shows Promise in CLL - Targeted Oncology
Venetoclax Consolidation After BTKi Shows Promise in CLL Targeted Oncology
Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML - OncLive
Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML OncLive
Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL - Pharmacy Times
Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL Pharmacy Times
Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL - OncLive
Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL OncLive
Venetoclax/azacitidine for the treatment of acute myeloid leukemia: real-life experience prospect...
Venetoclax/azacitidine for the treatment of acute myeloid leukemia: real-life experience prospective single center study Via Medica Journals
Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Como...
‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML - Healio
‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML Healio
Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL - Ly...
Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL Lymphoma Hub
Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple M...
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MD...
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS OncLive
Inqovi Plus Venclexta Approved for Certain Patients With ALL - Clinical Oncology News
Inqovi Plus Venclexta Approved for Certain Patients With ALL Clinical Oncology News
SEQUOIA Arm D results: Zanubrutinib + venetoclax in patients with TN CLL/SLL - Lymphoma Hub
SEQUOIA Arm D results: Zanubrutinib + venetoclax in patients with TN CLL/SLL Lymphoma Hub